Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Edesa Biotech Company

EDSA
CA27966L1085
A2PL1Q

Price

3.40
Today +/-
+0.06
Today %
+2.08 %
P

Edesa Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Edesa Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Edesa Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Edesa Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Edesa Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Edesa Biotech Stock Price History

DateEdesa Biotech Price
10/30/20243.40 undefined
10/29/20243.33 undefined
10/28/20243.40 undefined
10/25/20243.40 undefined
10/24/20243.31 undefined
10/23/20243.68 undefined
10/22/20243.76 undefined
10/21/20243.82 undefined
10/18/20244.06 undefined
10/17/20244.10 undefined
10/16/20244.07 undefined
10/15/20244.16 undefined
10/14/20244.30 undefined
10/11/20244.05 undefined
10/10/20244.08 undefined
10/9/20244.19 undefined
10/8/20244.30 undefined
10/7/20244.24 undefined
10/4/20244.26 undefined
10/3/20244.27 undefined
10/2/20244.68 undefined

Edesa Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Edesa Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Edesa Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Edesa Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Edesa Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Edesa Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Edesa Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Edesa Biotech’s growth potential.

Edesa Biotech Revenue, EBIT and net profit per share

DateEdesa Biotech RevenueEdesa Biotech EBITEdesa Biotech Net Income
2026e0 undefined-14.48 M undefined-4.71 M undefined
2025e0 undefined-11.12 M undefined-6.4 M undefined
2024e0 undefined-8.57 M undefined-7.14 M undefined
20230 undefined-9.22 M undefined-8.37 M undefined
20220 undefined-18.37 M undefined-17.55 M undefined
20210 undefined-23.68 M undefined-13.34 M undefined
2020330,000 undefined-6.4 M undefined-6.36 M undefined
2019410,000 undefined-2.83 M undefined-2.78 M undefined
2018210,000 undefined-5.08 M undefined-5.04 M undefined
2017230,000 undefined-5.22 M undefined-5.03 M undefined
20161.27 M undefined-4.91 M undefined-5.03 M undefined
2015760,000 undefined-4.34 M undefined-2.84 M undefined
2014370,000 undefined-5.72 M undefined-8.44 M undefined
2013550,000 undefined-3.85 M undefined-14.5 M undefined
2012290,000 undefined-6.52 M undefined-5.2 M undefined
2011700,000 undefined-4.84 M undefined-3.6 M undefined
2010850,000 undefined-970,000 undefined-590,000 undefined
20090 undefined-60,000 undefined-60,000 undefined
20080 undefined-20,000 undefined-20,000 undefined

Edesa Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
000000001,0000000000000
-------------------
-------------------
0000000000000000000
000-4-6-3-5-4-4-5-5-2-6-23-18-9-8-11-14
---------400.00----------
000-3-5-14-8-2-5-5-5-2-6-13-17-8-7-6-4
----66.67180.00-42.86-75.00150.00---60.00200.00116.6730.77-52.94-12.50-14.29-33.33
000.010.010.010.110.150.160.030.030.410.721.231.732.382.86000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Edesa Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Edesa Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2008200920102011201220132014201520162017201820192020202120222023
                               
0.050.224.1517.8613.898.9711.416.5710.35.037.217.847.095.36
000.570.040.020.020.060.160.0900.040.220.093.31.260.63
000001600000000000
00000005602507022000000
1002040309013018036012090400800950750448.91
0.060.22.594.231.058.1314.089.8712.116.7610.655.658.112.099.16.44
000.090.340.330.250.390.50.760.881.060.070.170.110.030.1
0000000070705000000
0000000000000000
000.20.170.150.120000002.482.382.282.18
0000000000000000
300102020202020202020000170173.49
0.0300.30.530.50.390.410.520.850.971.130.072.652.492.482.45
0.090.22.894.761.558.5214.4910.3912.967.7311.785.7210.7514.5811.588.89
                               
0.10.232.616.548.0213.1836.2438.1147.2848.3556.6512.0120.9834.8942.4746.64
00.050.87005.16000000.331.554.8711.1813.04
-0.02-0.08-1.01-4.13-8.66-25.18-33.62-35.34-40.36-45.39-50.43-6.73-13.13-26.5-44.04-52.42
0000.651.494.655.085.235.394.445.06-0.34-0.29-0.21-0.21-0.21
0000000000000000
0.080.22.473.060.85-2.197.7812.317.411.285.279.1113.059.47.05
0.0100.420.160.430.420.530.660.620.320.490.461.461.382.121.75
00000000000070802074.71
00000.133.450.891.7200000000
0000000000000000
0000000000000000
0.0100.420.160.563.871.422.380.620.320.490.461.531.462.141.82
0000000000000000
0000000000000000
0001.530.136.845.35000000.120.070.040.02
0001.530.136.845.35000000.120.070.040.02
0.0100.421.690.6910.716.772.380.620.320.490.461.651.532.181.84
0.090.22.894.751.548.5214.4710.3812.937.7211.775.7310.7614.5811.588.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Edesa Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Edesa Biotech's financial health and stability.

Assets

Edesa Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Edesa Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Edesa Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Edesa Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2008200920102011201220132014201520162017201820192020202120222023
000-3-5-14-8-2-5-5-5-2-6-13-17-8
0000000000000000
0000000000000000
00000000000-20-320
00000113-100000321
0000000000000000
0000000000000000
000-2-3-2-4-4-4-4-4-4-4-13-12-6
0000000000000000
0000000001-460000
0000000001-460000
0000000000000000
0000000000000000
0000091007090714115
0025091007080714114
0024000000000000
0000000000000000
0022-365-43-201200-1
-0.02-0.03-0.82-2.93-4.03-2.81-4.55-4.68-4.91-5-5-4.86-5.02-13.67-12.29-6.64
0000000000000000

Edesa Biotech stock margins

The Edesa Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Edesa Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Edesa Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Edesa Biotech's sales revenue. A higher gross margin percentage indicates that the Edesa Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Edesa Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Edesa Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Edesa Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Edesa Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Edesa Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Edesa Biotech Margin History

Edesa Biotech Gross marginEdesa Biotech Profit marginEdesa Biotech EBIT marginEdesa Biotech Profit margin
2026e93.94 %0 %0 %
2025e93.94 %0 %0 %
2024e93.94 %0 %0 %
202393.94 %0 %0 %
202293.94 %0 %0 %
202193.94 %0 %0 %
202093.94 %-1,939.39 %-1,927.27 %
201975.61 %-690.24 %-678.05 %
2018-109.52 %-2,419.05 %-2,400 %
2017-134.78 %-2,269.57 %-2,186.96 %
201611.02 %-386.61 %-396.06 %
2015-10.53 %-571.05 %-373.68 %
2014-105.41 %-1,545.95 %-2,281.08 %
2013-10.91 %-700 %-2,636.36 %
2012-51.72 %-2,248.28 %-1,793.1 %
2011-44.29 %-691.43 %-514.29 %
201054.12 %-114.12 %-69.41 %
200993.94 %0 %0 %
200893.94 %0 %0 %

Edesa Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Edesa Biotech earnings per share therefore indicates how much revenue Edesa Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Edesa Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Edesa Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Edesa Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Edesa Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Edesa Biotech Revenue, EBIT and net profit per share

DateEdesa Biotech Sales per ShareEdesa Biotech EBIT per shareEdesa Biotech Earnings per Share
2026e0 undefined0 undefined-1.45 undefined
2025e0 undefined0 undefined-1.97 undefined
2024e0 undefined0 undefined-2.2 undefined
20230 undefined-3.23 undefined-2.93 undefined
20220 undefined-7.72 undefined-7.37 undefined
20210 undefined-13.69 undefined-7.71 undefined
20200.27 undefined-5.2 undefined-5.17 undefined
20190.57 undefined-3.93 undefined-3.86 undefined
20180.51 undefined-12.39 undefined-12.29 undefined
20177.67 undefined-174 undefined-167.67 undefined
201642.33 undefined-163.67 undefined-167.67 undefined
20154.75 undefined-27.13 undefined-17.75 undefined
20142.47 undefined-38.13 undefined-56.27 undefined
20135 undefined-35 undefined-131.82 undefined
201229 undefined-652 undefined-520 undefined
201170 undefined-484 undefined-360 undefined
201085 undefined-97 undefined-59 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Edesa Biotech business model

Edesa Biotech Inc is a Canadian-based company that focuses on the development of novel therapeutic drugs. The company was founded in 2015 and has since achieved numerous significant advancements and successes. Edesa Biotech is one of the most popular companies on Eulerpool.com.

Edesa Biotech SWOT Analysis

Strengths

1. Strong research and development capabilities.

2. Innovative products and technologies.

3. Diverse portfolio of potential treatments.

4. Strong intellectual property rights.

Weaknesses

1. Limited financial resources for large-scale development and commercialization.

2. Reliance on external partnerships for clinical trials and distribution.

3. Lack of proven track record in bringing products to market.

4. Limited market presence and brand recognition.

Opportunities

1. Growing demand for innovative medical treatments.

2. Potential partnerships and collaborations in the biotechnology industry.

3. Expansion into emerging markets with unmet medical needs.

4. Favorable regulatory environment for biotech companies.

Threats

1. Intense competition from established biotech companies.

2. Stringent regulatory requirements for drug approval.

3. Uncertain reimbursement policies by healthcare payers.

4. Potential delays and setbacks in clinical trials and product development.

Edesa Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Edesa Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Edesa Biotech shares outstanding

The number of shares was Edesa Biotech in 2023 — This indicates how many shares 2.859 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Edesa Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Edesa Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Edesa Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Edesa Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Edesa Biotech stock splits

In Edesa Biotech's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Edesa Biotech.

Edesa Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.59 -0.52  (12.1 %)2024 Q3
3/31/2024-0.71 -0.58  (17.99 %)2024 Q2
12/31/2023-1.23 -0.54  (56.25 %)2024 Q1
9/30/2023-0.72 -0.6  (16.76 %)2023 Q4
6/30/2023-1.24 -0.7  (43.44 %)2023 Q3
3/31/2023-1.24 -0.84  (32.13 %)2023 Q2
12/31/2022-1.36 -0.91  (32.92 %)2023 Q1
9/30/2022-2.82 -0.14  (95.04 %)2022 Q4
6/30/2022-3.07 -2.59  (15.64 %)2022 Q3
3/31/2022-2.62 -2.31  (11.76 %)2022 Q2
1
2
3

Edesa Biotech shareholders

%
Name
Stocks
Change
Date
15.61194 % Nijhawan (Pardeep)507,388313,8654/2/2024
10.36006 % Pardeep Nijhawan Medicine Professional Corporation336,70201/8/2024
7.22418 % Lumira Ventures234,78604/2/2024
1.90769 % CM Management, LLC62,0002,34312/31/2023
0.98502 % Digestive Health Clinic Inc.32,01301/8/2024
0.54366 % Brooks (Michael J Ph.D.)17,66904/2/2024
0.50292 % The Vanguard Group, Inc.16,34550812/31/2023
0.45169 % Geode Capital Management, L.L.C.14,680-412/31/2023
0.38382 % Niffenegger (Kathi CPA)12,47404/2/2024
0.34871 % Dimensional Fund Advisors, L.P.11,33311,33312/31/2023
1
2
3
4
...
5

Edesa Biotech Executives and Management Board

Dr. Pardeep Nijhawan52
Edesa Biotech Chief Executive Officer, Corporate Secretary, Director (since 2019)
Compensation 601,731
Dr. Michael Brooks44
Edesa Biotech President
Compensation 552,732
Mr. Sean Macdonald46
Edesa Biotech Independent Chairman of the Board
Compensation 85,469
Mr. Carlo Sistilli65
Edesa Biotech Independent Director
Compensation 75,383
Mr. Frank Oakes72
Edesa Biotech Director (since 2010)
Compensation 61,681
1
2

Edesa Biotech Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Sotera Health Stock
Sotera Health
SupplierCustomer-0,530,660,320,640,79-
1

Most common questions regarding Edesa Biotech

What values and corporate philosophy does Edesa Biotech represent?

Edesa Biotech Inc represents values of innovation, integrity, and dedication to improving patients' lives. The company's corporate philosophy revolves around conducting cutting-edge research and development in dermatology and gastroenterology to address unmet medical needs. Edesa Biotech Inc emphasizes collaboration with healthcare professionals, patients, and partners to bring novel therapeutics to market. With a focus on scientific expertise and a commitment to delivering safe and effective treatments, Edesa Biotech Inc strives to make a lasting impact in the world of healthcare.

In which countries and regions is Edesa Biotech primarily present?

Edesa Biotech Inc is primarily present in North America, including the United States and Canada.

What significant milestones has the company Edesa Biotech achieved?

Edesa Biotech Inc has achieved several significant milestones. Firstly, the company received clearance from the U.S. FDA for its Phase 2b clinical trial of EB01, a potential treatment for chronic allergic contact dermatitis. Secondly, Edesa Biotech successfully completed a Phase 2a clinical trial, demonstrating the efficacy and safety of EB01 for the same indication. Additionally, the company expanded its intellectual property portfolio by securing U.S. and international patents for EB01. Furthermore, Edesa Biotech has established collaborations with leading academic institutions and renowned experts in dermatology. These achievements reflect the company's dedication to advancing innovative therapies for dermatological conditions and position Edesa Biotech as a prominent player in the biotech industry.

What is the history and background of the company Edesa Biotech?

Edesa Biotech Inc, founded in 2015, is a clinical-stage biopharmaceutical company headquartered in Markham, Ontario, Canada. The company focuses on developing innovative solutions for dermatological and inflammatory diseases. Edesa Biotech leverages its expertise in the field to discover and develop novel drug candidates, aiming to address unmet medical needs. With a strong pipeline and partnerships with leading institutions, Edesa Biotech aims to transform the treatment landscape for various skin conditions. As a forward-thinking biotech company, Edesa Biotech Inc continues to strive towards delivering groundbreaking therapies and improving patients' quality of life.

Who are the main competitors of Edesa Biotech in the market?

The main competitors of Edesa Biotech Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Amgen Inc.

In which industries is Edesa Biotech primarily active?

Edesa Biotech Inc is primarily active in the biotechnology industry.

What is the business model of Edesa Biotech?

The business model of Edesa Biotech Inc revolves around developing and commercializing novel, dermatology-focused therapies. With a strong emphasis on research and development, Edesa Biotech focuses on identifying and addressing unmet medical needs in the field of dermatology. By leveraging their expertise and advanced technologies, the company aims to develop innovative treatments that improve patient outcomes and quality of life. With a commitment to scientific excellence and strategic partnerships, Edesa Biotech Inc aims to revolutionize the dermatology industry with their cutting-edge products and therapies.

What is the P/E ratio of Edesa Biotech 2024?

The Edesa Biotech P/E ratio is -1.36.

What is the P/S ratio of Edesa Biotech 2024?

The Edesa Biotech P/S ratio is 0.

What is the Quality Investing of Edesa Biotech?

The Quality Investing for Edesa Biotech is 4/10.

What is the revenue of Edesa Biotech 2024?

The revenue cannot currently be calculated for Edesa Biotech.

How high is the profit of Edesa Biotech 2024?

The expected Edesa Biotech profit is -7.14 M USD.

What is the business model of Edesa Biotech

Edesa Biotech is a biopharmaceutical company that specializes in developing innovative therapies for patients with unmet medical needs. The company consists of an experienced group of executives and scientists dedicated to the discovery and development of successful therapeutic treatments. The business model of Edesa Biotech is based on the development of drugs for various diseases. The company has three business areas: dermatology, cardiovascular diseases, and infectious diseases. In the dermatology field, Edesa Biotech is focused on developing products for the treatment of skin conditions such as eczema and psoriasis. In the cardiovascular diseases field, the company is focused on developing therapies for the treatment of acute heart failure and cardiovascular failure. In the infectious diseases field, Edesa Biotech is working on the development of therapeutics for the treatment of severe viral infections such as COVID-19. Edesa Biotech has developed a pipeline of drug candidates in various stages of clinical development. The company has a wide range of technologies, including platform technologies such as the antibody-mediated zinc finger protein (AMZFP) technology. This technology uses artificial proteins to specifically target and deliver therapeutic agents within cells. Edesa Biotech also collaborates with strategic partners to accelerate the development and commercialization of new therapeutics. The company has agreements with suppliers and service providers to support both the development and manufacturing of drug candidates. Additionally, Edesa Biotech has signed an agreement with DDI Pharmaceuticals for the global marketing of one of its products. In the past, Edesa Biotech has also formed partnerships with pharmaceutical companies such as Novartis and Sanofi. This collaboration has enabled Edesa Biotech to leverage its technologies and expertise to develop and market new therapeutics. Overall, Edesa Biotech has a strong business model based on innovative technologies and strategic partnerships. The company is committed to working with its partners to develop new therapeutics that meet the unmet needs of patients with serious diseases. With its broad pipeline of drug candidates and strong strategic partnerships, Edesa Biotech has the potential to become a key player in the pharmaceutical industry in the future.

What is the Edesa Biotech dividend?

Edesa Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Edesa Biotech pay dividends?

The dividend cannot currently be calculated for Edesa Biotech or the company does not pay out a dividend.

What is the Edesa Biotech ISIN?

The ISIN of Edesa Biotech is CA27966L1085.

What is the Edesa Biotech WKN?

The WKN of Edesa Biotech is A2PL1Q.

What is the Edesa Biotech ticker?

The ticker of Edesa Biotech is EDSA.

How much dividend does Edesa Biotech pay?

Over the past 12 months, Edesa Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Edesa Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Edesa Biotech?

The current dividend yield of Edesa Biotech is .

When does Edesa Biotech pay dividends?

Edesa Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Edesa Biotech?

Edesa Biotech paid dividends every year for the past 0 years.

What is the dividend of Edesa Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Edesa Biotech located?

Edesa Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Edesa Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Edesa Biotech from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Edesa Biotech pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Edesa Biotech in the year 2023?

In the year 2023, Edesa Biotech distributed 0 USD as dividends.

In which currency does Edesa Biotech pay out the dividend?

The dividends of Edesa Biotech are distributed in USD.

All fundamentals about Edesa Biotech

Our stock analysis for Edesa Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edesa Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.